Market Overview

Shkreli Thinks Raptor Pharmaceutical's Valuation Was Too Low

Shkreli Thinks Raptor Pharmaceutical's Valuation Was Too Low
Related RPTP
Benzinga's Top Downgrades
Benzinga's M&A Chatter for Monday September 12, 2016

Shares of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) were trading higher by more than 20 percent Monday after the company agreed to be acquired by Horizon Pharma PLC (NASDAQ: HZNP) for $800 million, or $9 per share.

Speaking as a guest on Monday's Premarket Prep, Martin Shkreli shared his take on the deal and discussed the industry as a whole.

Related Link: Raptor Jumps 20% After Horizon Pharma's $800 Million Takeover Agreement

According to Shkreli, the premium that Horizon Pharma paid to acquire Raptor was "pretty modest" and he was expecting a price tag on any acquisition deal should have been "a lot more."

As a whole, Shkreli doesn't see any "over exuberant" valuations in the space.

Shares of Raptor Pharma traded recently at $64.61, up about 8 percent on the day.

Catch our full interview below. 

PreMarket Prep is a daily trading ideas show that focuses on technical analysis and actionable short term trades. You can listen to the show live every morning from 8-9 ET here, or catch the podcast here.  

Posted-In: Benzinga Pre Market Prep Biotechnology ValuationBiotech News M&A Exclusives Interview General


Related Articles (RPTP + HZNP)

View Comments and Join the Discussion!